Johnson & Johnson announces new long-term data from Quasar LTE study

Johnson & Johnson announced new long-term data from the Quasar long-term extension, LTE, study showing that Tremfya sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. These data are among the 30 company-sponsored abstracts being presented at the European Crohn’s and Colitis Organisation, ECCO, 2026 conference. At Week 140, 80.8% of patients taking TREMFYA(R) were in clinical remissiona. Additionally, 78.6% of patients achieved histo-endoscopic mucosal improvement (HEMI)b, and 53.6% of patients were in endoscopic remissionc, respectively.d Approximately 89% of eligible study participants combined completed treatment through Week 140. Nearly all participants who achieved clinical remission at Week 140 were corticosteroid-free for at least eight weeks.